Across TCGA pan-cancer cohorts, ELAPOR1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ELAPOR1 data layer compared with 28 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher ELAPOR1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ELAPOR1 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.
COAD, PDAC, and LSCC are the cancer types where ELAPOR1 mass-spec protein most reproducibly stratifies survival.